NEW YORK, December 1, 2016 /PRNewswire/ --
This morning, Stock-Callers.com observes the most recent performancesof these Medical Instruments and Supplies equities: TransEnterix Inc. (NYSE MKT: TRXC), Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Co. (NYSE: BDX), and OraSure Technologies Inc. (NASDAQ: OSUR). These companies belong to the Healthcare sector
On Wednesday, shares in Morrisville, North Carolina headquartered TransEnterix Inc. recorded a trading volume of 351,344 shares. The stock ended the session 2.56% lower at $1.52. The Company's shares have gained 1.33% in the last one month and 10.95% over the previous three months. The stock is trading 7.77% below its 50-day moving average. Moreover, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have a Relative Strength Index (RSI) of 43.99.
On November 09th, 2016, TransEnterix reported revenue of $1.5 million for Q3 2016, representing the sale of one Senhance system and related instruments and service, net of deferred revenue. The Company reported net loss of $12.9 million, or $0.11 per share, for Q3 2016, compared to $13.9 million, or $0.16 per share, in Q3 2015. The Company had cash, cash equivalents, and restricted cash of approximately $52.9 million as of September 30th, 2016. Your complete research report on TRXC can be retrieved for free at:
Irvine, California headquartered Endologix Inc.'s stock closed the day 0.82% higher at $7.35. A total volume of 1.85 million shares was traded, which was above their three months average volume of 1.30 million shares. The Company's shares are trading 32.64% below their 50-day moving average. Additionally, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 27.11.
On November 16th, 2016, Endologix announced that the U.S FDA has requested the Company to provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix® EndoVascular Aneurysm Sealing System. The Company expects these data to be available and submitted to the FDA in Q2 of 2017, followed by a possible FDA advisory panel meeting by the end of 2017, and potential FDA PMA approval of Nellix in Q2 2018.
On November 17th, 2016, research firm Canaccord Genuity downgraded the Company's stock rating from 'Buy' to 'Hold'. The research firm also revised downwards its previous target price from $13.50 to $7.50. ELGX free report is just a click away at:
Shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. recorded a trading volume of 1.35 million shares, which was higher than their three months average volume of 1.03 million shares. The stock ended yesterday's trading session 2.10% lower at $169.10. The Company's shares have advanced 0.71% in the past month and 11.07% since the start of this year. The stock is trading above its 200-day moving average by 1.77%. Furthermore, shares of Becton, Dickinson and Co., which develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide, have an RSI of 45.81.
On November 21st, 2016, Becton, Dickinson's Board of Directors declared a quarterly dividend of $0.73 per common share, an increase of 10.6% from the previous quarter. The dividend will be payable on December 30th, 2016, to holders of record on December 09th, 2016. The indicated annual dividend rate for FY17 is $2.92 per share. Sign up for your complimentary research report on BDX at:
Bethlehem, Pennsylvania-based OraSure Technologies Inc.'s stock finished Wednesday's session flat at $8.43 with a total trading volume of 510,094 shares. The Company's shares have advanced 12.25% in the last one month and 30.90% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 5.48% and 14.95%, respectively. Additionally, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have an RSI of 56.13.
On November 29th, 2016, OraSure Technologies announced that it will begin fulfilling a contract to supply a foreign government with $18 million of product, primarily to support a nationwide hepatitis C (HCV) testing and treatment program with the goal of eliminating HCV infection across the country by 2020. The contract calls for the purchase of $16 million of OraQuick® HCV Rapid Antibody Tests and $2 million of OraQuick® Rapid HIV-1/2 Antibody Tests. Register for free on Stock-Callers.com and download the latest research report on OSUR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All